Belvedere Trading
TGTX icon

Belvedere Trading’s TG Therapeutics TGTX Stock Holding History

Belvedere Trading’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1,400
Closed -$11.7K – 1006
2023
Q3 		$11.7K Hold
1,400
– – ﹤0.01% 535
2023
Q2 		$34.8K Buy
+1,400
New +$36.2K ﹤0.01% 593
2023
Q1 		– Sell
-42,000
Closed -$497K – 1404
2022
Q4 		$497K Buy
+42,000
New +$305K ﹤0.01% 132

Other funds holding TGTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Belvedere Trading's TGTX Position: Q4 2023 in Review

Belvedere Trading sold out of TG Therapeutics (TGTX) in Q4 2023, closing a stake of 7,020 shares — an estimated $58.7K sold.

Belvedere Trading first reported a position in TGTX in Q1 2022 and held it in 6 quarters. The position peaked at $531K in Q4 2022. 235 funds tracked by Wall St. Rank hold TGTX as of Q4 2023.

  • Belvedere Trading reported no remaining TG Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Belvedere Trading sold 7,020 TG Therapeutics shares in Q4 2023, an estimated $58.7K.
  • Belvedere Trading first reported a position in TG Therapeutics in Q1 2022 and held it in 6 quarters.
  • Belvedere Trading's TG Therapeutics position peaked at $531K in Q4 2022.
  • 235 funds tracked by Wall St. Rank held TG Therapeutics as of Q4 2023.

Based on Belvedere Trading's 13F filing for Q4 2023, filed 13 Feb 2024.